City File: Fisons
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AFTER a dismal 18 months, Fisons should be able to give its bedraggled shareholders some hope on Tuesday by maintaining its dividend. Such a sign might go some way to wiping out the bad feeling left by a 45 per cent drop in the company's share price, the resignation of its chairman and an unpleasant and costly spat with the US Food & Drug Administration.
The plus points for the largest company in Ipswich are the US approval of its Tilade anti-asthma drug, a co-marketing agreement with Rhone-Poulenc Rorer and the raising of nearly pounds 200m from disposals.
At 221p, the shares have discounted a 40 per cent fall in the profits to pounds 110m and are looking forward to an improvement to pounds 150m next year. Buy.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments